Levonicopto (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This inhibition halts bacterial cell division and leads to bacterial death, offering bactericidal activity against a wide range of Gram‑positive and Gram‑negative organisms.

The dosing regimen for Levonicopto is determined by the prescribing clinician based on the infection severity, patient age, and response to therapy. The prescriber will specify the number of drops, frequency, and duration appropriate for each indication.

Safety data for Levonicopto in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order Levonicopto, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levonicopto (levofloxacin) offers a broader spectrum and higher potency against many resistant strains compared with older agents such as ciprofloxacin. Compared with moxifloxacin, it has similar efficacy but a slightly different safety profile, allowing clinicians to choose based on pathogen susceptibility and patient tolerance.

Levonicopto should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light and moisture, and discard any solution that appears discolored or contains particles.

Levonicopto is applied as eye drops. The patient should wash hands, tilt the head back, pull down the lower eyelid, instill the prescribed number of drops, and close the eye gently for a few seconds. Contact lenses should be removed before administration and re‑inserted after the recommended interval.

Serious adverse reactions include severe allergic responses such as angioedema or anaphylaxis, corneal ulceration or perforation, and significant visual loss. Patients should seek immediate medical attention if they experience intense eye pain, swelling, rapid vision changes, or signs of a systemic allergic reaction.

Levonicopto is contraindicated in individuals with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation. It should also be avoided in patients with a history of tendon disorders related to fluoroquinolone use, unless the benefits outweigh the risks.